CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

This study is testing a new type of immunotherapy called CAR-NK cell therapy (CL-NK-001) for adults with advanced, metastatic, or recurrent pancreatic cancer. NK cells are natural killer cells from the immune system, and these have been genetically engineered to recognize and attack pancreatic cancer cells. This is an early-phase study to test the safety and initial effectiveness of this approach. **You may be eligible if...** - You are between 18 and 70 years old - You have locally advanced, metastatic, or recurrent pancreatic cancer - Your tumor has been confirmed to express a protein called eGR1 (by tissue test) - Standard treatments have failed, you cannot tolerate them, or you have declined them - Your cancer has at least one measurable lesion on scans - You have not received anti-cancer treatment in the past 4 weeks **You may NOT be eligible if...** - Your general health is poor (ECOG performance status above 2) - You have significant problems with blood counts or organ function - Your life expectancy is less than 12 weeks Talk to your doctor to see if this trial is right for you.